Precision Biologics Parts Ways with NantCell, Dr. Soon-Shiong

As of July 29, 2019, Precision Biologics, Inc. is no longer affiliated with NantCell, Inc. NantWorks, or any other entity or individual associated with Dr. Patrick Soon-Shiong.  Since October 2015, NantCell had held approximately a 60% interest in Precision Biologics.  NantCell has now exited that investment, and Dr. Soon-Shiong and other representatives of NantCell have left the Precision Biologics board.  Dr. Philip M. Arlen, President and CEO of Precision Biologics, said “Now that we are independent, we are looking forward to being able to advance Precision Biologics’ research and clinical trials in a timely and cost effective manner. Our main focus will continue to be developing novel and effective treatments for cancer patients.” 

Diagnostics

Our monoclonal antibodies are designed to target the tumor without harming healthy cells.

Therapeutics

Our unique platform, combined with breakthroughs in biotechnology, enable us to produce targeted antibodies that weren’t possible just a few years ago.

Unique Discovery Platform

We have a platform of patient tumor derived anticancer vaccines.

Clinical Trials

Precision Biologics is dedicated to improving the lives of cancer patients through its innovative therapeutic and diagnostic products. The company’s therapeutic program is focused on developing new drugs that can improve outcomes, extend survival, and improve the overall quality of life. The goal of the diagnostic program is to develop products that will enable earlier detection, and the potential for earlier intervention. Our current clinical trials are directed toward patients with late-stage pancreatic and colorectal cancer.

SITC 2019


Immuno-Oncology Europe 2019


Dr. Philip M Arlen, will be representing Precision Biologics in the PLENARY KEYNOTE SESSION – Cambridge Healthtech Institute August 8-9, 2019


The National Cancer Institute opens Clinical trial testing safety and dosing of NEO-201 antibody in patients with advanced cancer


Precision Biologics along with Dr Christina Annunziata, MD, PhD, from the NCI are presenting at the AACR Annual Meeting


Precision Biologics manuscript on our NEO-201 Antibody article published in Frontiers in Immunology


Dr. Philip Arlen to Speak at Immuno-Oncology Summit


Dr. Philip Arlen to Speak at 2nd Annual Advances in Immuno-oncology Congress


Dr. Philip Arlen to Speak at PEGS Boston 2017


Dr. Philip Arlen to Speak at the Biomarkers & Immuno-Oncology World Congress 2017


Precision Biologics to Highlight Preclinical Data on NEO-201, a Neoantigen Targeting Antibody in Oral Presentation at the 110th Annual Meeting of the American Association of Clinical Research


Dr. Philip Arlen to Speak at Immuno-Oncology Breakthroughs – Novel Cancer Therapies meeting


Dr. Philip Arlen to Speak at ImmunoTX Summit – The Discovery and Development of Novel Monoclonal Antibodies Targeting Neoantigens


Cancer Breakthroughs 2020 Milestone: The Nation’s First Neoepitope Antibody Immunotherapy Phase II Trial Demonstrating Safety and Prolonged Survival in Patients with Metastatic End-Stage Colon Cancer


Immune Profiling World Congress – 11-12 October 2016, Fairmont Rey Juan Carlos


Biomarkers & Precision Medicine USA Congress – 3-4 October 2016, San Diego


2016 ASCO Annual Meeting


Precision Biologics, a NantWorks Company, to Present Combination Immunotherapy of a Novel NEO-Epitope Antibody Targeting Ovarian and Uterine Cancer at the AACR Annual Meeting 2016


NCI Investigators Collaborate with Breakthroughs 2020
Twitter


Cancer Breakthroughs 2020 Reaches First Clinical Trial Milestone: Immunotherapy Trial Demonstrates Encouraging Survival Rates in Patients with Metastatic Colorectal Cancer‎ Who Failed all Standard Therapy


Beth Israel Deaconess Medical Center (BIDMC) Joins Precision Biologics as Collaborators on Phase 2B Pancreatic Cancer Trial

Science & Research Facility info@precision-biologics.com 301-500-8646 F:240-669-9828 4814 Del Ray Avenue, Bethesda, MD 20814